Pathway Genomics welcomed strategic partner IBM Watson to its customer base in a round that lifted its overall funding to more than $130m.
US-based precision medicine developer Pathway Genomics has secured more than $40m in a series E round that included IBM Watson, computing company IBM’s cloud data subsidiary.
Pathway did not disclose the other investors in the round, which increased Pathway’s overall funding to more than $130m. It expects to raise additional series E funding in the first quarter of this year.
Founded in 2008, Pathway operates a medical laboratory that provides precision healthcare information covering cancer risk, cardiac health, inherited diseases,…
